MRT-92 is a Smoothened (Smo) antagonist (Ki=0.7 nM) with anticancer activity. MRT-92 inhibits Hedgehog signaling pathway and rodent cerebellar granule cell proliferation by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor (IC50=0.4 nM). MRT-92 can be used in the study of cerebellar glioma[1].
References
[1] Hoch, et al. "MRT-92 inhibits Hedgehog signaling by blocking overlap** binding sites in the transmembrane domain of the Smoothened receptor." The FASEB Journal 29.5 (2015): 1817. DOI:10.1096/fj.14-267849
